Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.
Joseph Ciccolini, PhD
Advertisement
Articles by Joseph Ciccolini, PhD
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses residual concentrations of cetuximab (Erbitux) in patients with head and neck cancer.
Advertisement
Latest Updated Articles
Dr. Ciccolini on Residual Concentrations of Cetuximab in Head and Neck CancerPublished: April 6th 2017 | Updated:
Exploring Residual Concentrations of Agents in Head and Neck CancerPublished: April 10th 2017 | Updated:
Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck CancerPublished: April 21st 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5